Magnesium silicate

Identification

Name
Magnesium silicate
Accession Number
DB13249
Type
Small Molecule
Groups
Approved
Description

Magnesium silicate is a compound of magnesium oxide and silicon. It is the magnesium salt of silicic acid containing an unspecified amount of water. The molecular formula can be expressed more clearly as MgSiO3.xH2O.[1] It is known as talc and it presents many uses in the cosmetic industry, food industry and pharmaceutical industry.[2] Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.[3]

Structure
Thumb
Synonyms
Not Available
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Formula ECMagnesium silicate (12.5 mg) + Calcium (250 mg) + Copper (0.5 mg) + Ergocalciferol (100 unit) + Magnesium (125 mg) + Manganese (2.5 mg) + Pyridoxine hydrochloride (2.5 mg) + Zinc (3.75 mg)TabletOralBody Wise International LlcNot applicableNot applicableCanada
Categories
UNII
9B9691B2N9
CAS number
1343-88-0
Weight
Average: 100.387
Monoisotopic: 99.9467121
Chemical Formula
MgO3Si
InChI Key
ZADYMNAVLSWLEQ-UHFFFAOYSA-N
InChI
InChI=1S/Mg.3O.Si/q+2;3*-2;+4
IUPAC Name
silicon(4+) ion magnesium(2+) ion trioxidandiide
SMILES
[O--].[O--].[O--].[Mg++].[Si+4]

Pharmacology

Indication

Magnesium silicate is used to absorb moisture, prevent caking, and to improve the feel of a product. In the pharmaceutical companies, it is used as a dietary supplement, as part of the formulation ingredients in drug production, in antacid and antiulcer preparations, as a component of antiepileptic drugs, in antifungal topical agents and in the treatment of acne and as a facial moisturizer.[2]

When complexed with arginine, magnesium silicate can be used as an antiatherosclerotic agent and to promote bone and cartilage formation in mammals.[1]

Pharmacodynamics
Not Available
Mechanism of action

As a supplement, magnesium silicate acts by replacing the factor that is missing. In the case of antacids, it is a non-absorbable antacid whose main activity is related to the absorption of hydrochloric acid. More specifically, magnesium silicate acts as a neutralizing and astringent agent.[5]

Absorption

Orally administered magnesium silicate is rapidly neutralized in the stomach and it forms magnesium chloride and silicon dioxide. From the modified portion, some of the formed magnesium is absorbed.[1] The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.[5]

Volume of distribution

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.[5]

Protein binding

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.[5]

Metabolism

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.[5]

Route of elimination

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.[5]

Half life

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.[5]

Clearance

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.[5]

Toxicity

The administration of more than 50 meq of magnesium daily can produce the development of hypermagnesemia. This can provoke the formation of bladder and renal calculi. There is no known toxicity and the LD50 in animals are higher than 500 mg/kg in humans.[1] It is determined that magnesium silicate is not carcinogenic.[4]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium silicate.
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium silicate.
2,5-Dimethoxy-4-ethylamphetamineMagnesium silicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.
2,5-Dimethoxy-4-ethylthioamphetamineMagnesium silicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.
3,4-MethylenedioxyamphetamineMagnesium silicate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Magnesium silicate.
AcepromazineMagnesium silicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AceprometazineMagnesium silicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetaminophenMagnesium silicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magnesium silicate.
Food Interactions
Not Available

References

General References
  1. Rashid I., Nidal H. Daraghmeh M., Omari A., Babur Z., Chowdhry S., Leharne H., Adnan A. (2011). Profiles of drug substances and related methodology. Academic Press. [ISBN:978-0-12-387667-6]
  2. FDA Ingredients [Link]
  3. FDA code of federal regulations [Link]
  4. Toxnet [Link]
  5. Lecture [File]
External Links
ChemSpider
32698785
Wikipedia
Talc
ATC Codes
A02AA05 — Magnesium silicate
MSDS
Download (47.4 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)1910 ºC'MSDS'
water solubilityInsolubleMonograph
Predicted Properties
PropertyValueSource
logP-0.65ChemAxon
pKa (Strongest Acidic)15.7ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity13.11 m3·mol-1ChemAxon
Polarizability0.95 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal organides
Sub Class
Alkaline earth metal oxides
Direct Parent
Alkaline earth metal oxides
Alternative Parents
Metalloid salts / Inorganic salts / Inorganic oxides
Substituents
Alkaline earth metal oxide / Inorganic oxide / Inorganic salt / Inorganic metalloid salt
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 23, 2017 14:38 / Updated on August 02, 2018 06:49